The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of FASN mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of FASN protein]
alliin inhibits the reaction [Isoproterenol results in increased activity of HMGCR protein] alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of HMGCR mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of HMGCR protein]
alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF1 mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF1 protein]
alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF2 mRNA]; alliin inhibits the reaction [1,3-dichloro-2-propanol results in increased expression of SREBF2 protein]
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] [Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein] aloxistatin results in increased lipidation of MAP1LC3B protein [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein] aloxistatin results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein
IDH2 protein mutant form results in decreased abundance of Alanine Triazines inhibits the reaction [IDH2 protein mutant form results in decreased abundance of Alanine]
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]
Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]
Selenocysteine inhibits the reaction [Lipopolysaccharides affects the localization of and affects the activity of FOS protein]; Selenocysteine inhibits the reaction [Peroxynitrous Acid affects the localization of and affects the activity of FOS protein]
Selenocysteine inhibits the reaction [Lipopolysaccharides affects the localization of and affects the activity of RELA protein]; Selenocysteine inhibits the reaction [Peroxynitrous Acid affects the localization of and affects the activity of RELA protein]
LCL161 binds to and affects the activity of ABCB1 protein; LCL161 inhibits the reaction [ABCB1 protein results in increased export of Fluorescent Dyes]; LCL161 inhibits the reaction [ABCB1 protein results in increased export of mitotracker green FM]
DPP3 protein results in increased cleavage of Enkephalin, Leucine spinorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]; tynorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]
N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein N-Formylmethionine Leucyl-Phenylalanine results in increased activity of AKT1 protein 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [AKT1 protein binds to NCF1 protein]]; 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of AKT1 protein]; N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [AKT1 protein binds to NCF1 protein] cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of AKT1 protein]
[zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; ALOX5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein; SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein]
1-Butanol inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 1-Butanol inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]; ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] N-Formylmethionine Leucyl-Phenylalanine affects the localization of ARF6 protein
N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein]
Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]; Quercetin affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]; SB 203580 inhibits the reaction [Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]]
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of CTSG protein]
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of NCF1 protein] promotes the reaction [NCF1 protein binds to CYBA protein]]; [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of NCF1 protein] promotes the reaction [NCF1 protein binds to CYBA protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein diphenyleneiodonium inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein]; Genistein inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CYBB protein]
2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of ELANE protein]; [Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein; pirinixic acid analog inhibits the reaction [[Cytochalasin B co-treated with N-Formylmethionine Leucyl-Phenylalanine] results in increased secretion of ELANE protein]
1-Butanol inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with dihydrocytochalasin B] results in increased activity of FGR protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of FGR protein
N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein epigallocatechin gallate inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein]
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein]
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein]; nimesulide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein]
2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; dimemorfan inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Foropafant inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; KT 5720 inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; plaunotol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Staurosporine inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein] fMLP increases expression of ITGAM protein on neutrophils and monocytes [N-formyl-methionyl-leucyl-phenylalanine cotreated with midazolam] decreases expression of ITGAM protein on neutrophils
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; crenatoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; plaunotol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of LYN protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of LYN protein]
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; Grape Seed Proanthocyanidins inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pentoxifylline inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Qingdai compound inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein; resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein] RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK14 protein; Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein]
cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; Grape Seed Proanthocyanidins inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pentoxifylline inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Qingdai compound inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; Resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein; resveratrol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein] RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein] MAPK8 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Reactive Oxygen Species]; N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK8 protein
carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MPO protein] N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]; diphenyleneiodonium inhibits the reaction [manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]]; manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]; Sodium Azide inhibits the reaction [manganese chloride promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of MPO protein]]; wortmannin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; bisindolylmaleimide I inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein] N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of NCF1 protein 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of NCF1 protein] promotes the reaction [NCF1 protein binds to CYBA protein]]; 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF1 protein]; 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [AKT1 protein binds to NCF1 protein]]; 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [NCF1 protein binds to PAK1 protein]]; 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of NCF1 protein]; [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of NCF1 protein] promotes the reaction [NCF1 protein binds to CYBA protein]; N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [AKT1 protein binds to NCF1 protein]; N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [NCF1 protein binds to PAK1 protein]
N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF2 protein 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF2 protein]
N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF4 protein 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of NCF4 protein]
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PAK1 protein]; 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [NCF1 protein binds to PAK1 protein]]; N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased activity of PAK1 protein; N-Formylmethionine Leucyl-Phenylalanine promotes the reaction [NCF1 protein binds to PAK1 protein]
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PAK2 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of PLA2G5 protein PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid]; PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4] N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of PLA2G5 protein
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of PLCG2 protein]
PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of MAPK3 protein] PLD1 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Reactive Oxygen Species]
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCA protein]; N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCA protein
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCB protein]; N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCB protein
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCD protein]; N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCD protein
2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCZ protein]; N-Formylmethionine Leucyl-Phenylalanine affects the localization of and results in increased phosphorylation of PRKCZ protein
N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PTGS2 mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of PTGS2 protein
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein] 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; apilimod inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein N-Formylmethionine Leucyl-Phenylalanine results in decreased activity of RAC2 protein 2-benzyl-3-(4-hydroxymethylphenyl)indazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in decreased activity of RAC2 protein] 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]; apilimod inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]; RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK1 protein]; RAC2 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK3 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein]
RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC1 protein]; RHOG gene mutant form inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of RAC2 protein] RHOG protein affects the susceptibility to N-Formylmethionine Leucyl-Phenylalanine
ALOX5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; Foropafant inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; ITGA2B protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; MK-886 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; PTAFR protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; SR 121566 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]; zileuton inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of SELP protein]
N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; cyclosporin H inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; epsilon-viniferin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of SRC protein]
AG 1879 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of TEC protein]; honokiol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine affects the localization of TEC protein]
[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides; Cyclosporine inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]; Tacrolimus inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides] N-Formylmethionine Leucyl-Phenylalanine results in increased expression of TNF protein
Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; Masoprocol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA]; nordy inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of VEGFA protein] N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA mRNA; N-Formylmethionine Leucyl-Phenylalanine results in increased expression of VEGFA protein
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Orlistat results in decreased expression of ACACA mRNA
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]
orlistat results in increased activity of CASP3 protein orlistat results in increased cleavage of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA]
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA]
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein
Orlistat results in increased expression of CCND1 protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]
Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
orlistat results in increased phosphorylation of EIF2A protein orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
EIF2AK3 gene mutant form results in increased susceptibility to orlistat orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
ERBB2 protein affects the susceptibility to orlistat orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein orlistat affects the localization of ERBB2 protein
orlistat analog binds to FASN protein FASN protein affects the susceptibility to orlistat [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [Orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [Orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [Orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; Orlistat binds to and results in decreased activity of FASN protein; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; Orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] Orlistat results in decreased expression of FASN protein
orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased expression of GCG protein orlistat results in decreased secretion of GCG protein
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein]
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]
orlistat results in decreased expression of INS protein orlistat results in increased expression of INS protein orlistat affects the expression of INS protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
orlistat results in decreased activity of LPL protein orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] [orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Malondialdehyde]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased abundance of Triglycerides]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CCND1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of CD34 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of FASN protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of IL6 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PCNA protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of PTGS2 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK1 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of MAPK3 protein]; Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased phosphorylation of RPS6 protein]
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein]
Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein]
orlistat results in decreased activity of PLA2G7 protein [orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein
orlistat results in decreased secretion of PNLIP protein orlistat results in decreased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] orlistat affects the folding of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil]
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein]
Orlistat results in increased expression of PTEN protein Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in decreased expression of PTEN protein]
orlistat results in decreased secretion of PYY protein orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein]
[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein orlistat results in decreased expression of SKP2 protein
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of SREBF1 protein] Orlistat results in decreased expression of SREBF1 protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA
Orlistat inhibits the reaction [[AKT1 gene mutant form co-treated with MET gene mutant form] results in increased expression of TNF protein]; Orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF protein]
Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
Ritonavir results in decreased activity of ABCB11 protein Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]
Ritonavir results in decreased expression of ADIPOQ mRNA; Ritonavir results in decreased expression of ADIPOQ protein rosiglitazone inhibits the reaction [Ritonavir results in decreased secretion of ADIPOQ protein] diphenyleneiodonium inhibits the reaction [Ritonavir results in decreased expression of ADIPOQ protein]
diphenyleneiodonium inhibits the reaction [Ritonavir results in increased expression of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein] Ritonavir results in decreased expression of CCL2
Ritonavir results in increased expression of CDKN1A mRNA; Ritonavir results in increased expression of CDKN1A protein manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of CDKN1A protein]
Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]
Ritonavir results in increased expression of CYP3A4 mRNA Ritonavir results in decreased activity of CYP3A4 protein CYP3A4 protein binds to Ritonavir analog CYP3A4 protein affects the metabolism of Ritonavir
Acetylcysteine inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; FTI 277 inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]
Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of GPD1 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Acetylcysteine inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Bilirubin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; HMOX1 protein inhibits the reaction [Ritonavir results in increased expression of ICAM1 protein]; NFE2L2 protein mutant form inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA]; Ritonavir promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Lopinavir results in increased expression of HMOX1 mRNA]; Rotenone inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; tricarbonyldichlororuthenium (II) dimer promotes the reaction [Ritonavir results in increased expression of HMOX1 protein] Ritonavir results in increased expression of HMOX1 mRNA; Ritonavir results in increased expression of HMOX1 protein
Ritonavir results in increased expression of ICAM1 protein HMOX1 protein inhibits the reaction [Ritonavir results in increased expression of ICAM1 protein]
diphenyleneiodonium inhibits the reaction [Ritonavir results in increased expression of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein]; Ritonavir inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] rosiglitazone inhibits the reaction [Ritonavir results in increased expression of IL6 mRNA] Ritonavir results in increased expression of IL6 mRNA; Ritonavir results in increased expression of IL6 protein
Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]; Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein]; Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of GPD1 protein]; Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SREBF1 protein]
Ritonavir results in increased expression of NFE2L2 protein NFE2L2 protein mutant form inhibits the reaction [Ritonavir results in increased expression of HMOX1 mRNA]
Ritonavir results in decreased expression of NOTCH4 protein [Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of NOTCH4 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of NOTCH4 protein]
Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein] Ritonavir results in increased expression of PPARG mRNA
Ritonavir binds to and affects the localization of PRKCA protein Ritonavir results in increased activity of PRKCA protein Ritonavir results in increased expression of PRKCA protein
Ritonavir promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SREBF1 protein]
Ritonavir results in decreased expression of TJP1 protein [Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of TJP1 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of TJP1 protein]
Ritonavir results in decreased secretion of TNF protein rosiglitazone inhibits the reaction [Ritonavir results in increased expression of TNF mRNA] Ritonavir inhibits the reaction [IFNG protein results in increased secretion of TNF protein]; Ritonavir inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Ritonavir results in increased expression of TNF mRNA; Ritonavir results in increased expression of TNF protein
FTI 277 inhibits the reaction [Ritonavir results in increased expression of TP53 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]
selenomethylselenocysteine results in decreased expression of BCL2 mRNA selenomethylselenocysteine results in decreased expression of BCL2 protein [selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP3 protein modified form]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP6 protein modified form]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP9 protein modified form]; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of PARP1 protein modified form]; HDAC8 inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]; selenomethylselenocysteine metabolite inhibits the reaction [HDAC8 protein binds to BMF promoter]; selenomethylselenocysteine metabolite inhibits the reaction [STAT3 protein binds to BMF promoter]; selenomethylselenocysteine metabolite promotes the reaction [EP300 protein binds to BMF promoter]; selenomethylselenocysteine metabolite promotes the reaction [SP3 protein binds to BMF promoter]; STAT3 protein inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA] selenomethylselenocysteine metabolite results in increased expression of BMF protein selenomethylselenocysteine metabolite results in increased expression of BMF mRNA; selenomethylselenocysteine metabolite results in increased expression of BMF protein
selenomethylselenocysteine results in increased activity of CASP3 protein selenomethylselenocysteine metabolite results in increased expression of CASP3 protein modified form BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP3 protein modified form]
selenomethylselenocysteine metabolite results in increased expression of CASP6 protein modified form BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of CASP6 protein modified form]
selenomethylselenocysteine results in decreased expression of CCND1 protein selenomethylselenocysteine results in decreased expression of CCND1 mRNA; selenomethylselenocysteine results in decreased expression of CCND1 protein [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of CCND1 protein
selenomethylselenocysteine metabolite results in increased expression of CDKN1A protein [Aminooxyacetic Acid results in decreased metabolism of selenomethylselenocysteine] which results in decreased expression of CDKN1A protein
selenomethylselenocysteine results in decreased expression of COL1A1 mRNA; selenomethylselenocysteine results in decreased expression of COL1A1 protein
selenomethylselenocysteine results in decreased expression of COL1A2 mRNA; selenomethylselenocysteine results in decreased expression of COL1A2 protein
selenomethylselenocysteine results in decreased expression of ESR1 protein [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of ESR1 protein
selenomethylselenocysteine results in increased activity of GPX1 protein selenomethylselenocysteine results in increased expression of GPX1 mRNA; selenomethylselenocysteine results in increased expression of GPX1 protein
HDAC8 inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]; selenomethylselenocysteine metabolite inhibits the reaction [HDAC8 protein binds to BMF promoter]
[selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of MKI67 protein selenomethylselenocysteine results in decreased expression of MKI67 protein
selenomethylselenocysteine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; selenomethylselenocysteine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
[Aminooxyacetic Acid results in decreased metabolism of selenomethylselenocysteine] which results in decreased expression of PARP1 protein modified form; BMF protein promotes the reaction [selenomethylselenocysteine metabolite results in increased expression of PARP1 protein modified form]
selenomethylselenocysteine results in decreased expression of PGR protein [selenomethylselenocysteine co-treated with Tamoxifen] results in decreased expression of PGR protein
selenomethylselenocysteine metabolite inhibits the reaction [STAT3 protein binds to BMF promoter]; STAT3 protein inhibits the reaction [selenomethylselenocysteine metabolite results in increased expression of BMF mRNA]
SLC15A1 protein results in increased transport of Valganciclovir Valganciclovir inhibits the reaction [SLC15A1 protein results in increased transport of glycylsarcosine]
browse the term
